Global Health Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹1,469 Cr +33.7% YoYSee revenue, profit and what management said. You are viewing Q1 FY26.
GH

Global Health Ltd

Q1 FY26Healthcare Services

Global Health Q1 FY26 earnings call: Revenue & Margins

Q1 FY26 earnings call: what management said on revenue, margins and capex.

Revenue
₹1,031Cr
+19.7% YoY
+10.7% QoQ
Net profit
₹159Cr
+50% YoY
+57.4% QoQ
Margin
24%
+2 pp YoY
0 pp QoQ
Price₹1,410
Market cap₹37.9K Cr
P/E66.2

The short version

Medanta expects continued strong growth in patient volumes, evidenced by 14% inpatient and 13% outpatient volume growth year-on-year in Q1 FY26. Medanta projects strong growth opportunities driven by expansion and acquisitions aligned with their ecosystem and financial logic (Page 17).

From Global Health Ltd's Q1 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • Medanta expects continued strong growth in patient volumes, evidenced by 14% inpatient and 13% outpatient volume growth year-on-year in Q1 FY26.
  • Developing hospitals such as Lucknow and Patna show significant momentum towards operational maturity with increasing occupancy and volumes.
  • Expansion projects (South Delhi, Mumbai, Pitampura) are progressing, though expected commissioning timelines are uncertain; FY 2029-2030 is a tentative target.
  • New hospitals and bed capacity expansion (e.g., Noida starting with 300 beds scaling up, Ranchi expansion) will further drive volume growth.
  • Growth in revenue driven by a mix of higher realizations, more complex procedures (like oncology, robotic surgeries), and improved specialty mix.
  • International patient revenue, especially from Gurugram, is growing but remains a smaller portion of revenue.

2 more points from Global Health Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Global Health Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Medanta has a strong cash position with plenty of growth opportunities and ongoing capex commitments, particularly for building out existing hospitals in Delhi, Mumbai, and Guwahati. Bulk of this hospital build-out spend occurs in the last year of construction.
  • The company plans to operationalize the new 550-bed Noida hospital starting with about 300 beds, scaling to full capacity based on demand.
  • They are open to acquisitions, including traditional M&A, O&M contracts, and asset-light models, provided the acquisition fits Medanta’s quality standards, geographical strategy, and financial logic.

2 more points from Global Health Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Healthcare Services

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
Rev 1Mar 3
3
Rev 2Mar 1
4
Rev 2Mar 1
5
Rev 2Mar 1
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Global Health Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

Key points related to growth opportunities and projects include: - Medanta has a broad expansion pipeline with 2,000 beds planned over the next 3-4 years. - Near-term target to add 1,000 beds supported by advanced technology and expanded clinical teams. - Upcoming launch of 550-bed Medanta Noida facility expected operational soon. - Operationalized a 110-bed hospital in Ranchi recently. - Ongoing interior fit-out and commissioning of Tower B in Patna and floors in Lucknow to increase capacity.

2 more points from Global Health Ltd's call on order book

Create a free account to keep reading this call

Global Health Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Global Health Ltd Q1 FY26 results — key figures

Global Health Ltd Q1 FY26 reported results vs Q1 FY25, ₹ crore
₹ CrQ1 FY26Q1 FY25YoYQ4 FY25QoQ
Revenue1,031861+19.7%931+10.7%
Operating profit (EBITDA)247186+32.8%225+9.8%
Operating margin24%22%+2 pp24%0 pp
Profit before tax208144+44.4%133+56.4%
Net profit (PAT)159106+50%101+57.4%
EPS (₹)5.923.96+49.5%3.78+56.6%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹1.5K Cr, net profit ₹219 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Healthcare Services this season

  • Aster DM Quality (Q1 FY26)

    Recent quarters saw subdued volume growth due to leadership changes and seasonal effects, but an 8% volume growth was achieved in Q1 FY26, improving from 2% in…

  • Dr Agarwal's Hea (Q1 FY26)

    70 crores via preferential allotment to AEHL for CAPEX plans, particularly the flagship facility at Cathedral Road, indicating capacity and service…

  • Syngene International (Q1 FY26)

    Operating EBITDA grew 21% YoY in Q1 FY '26 with margins rising to ~24% from 22% last year. Key concall takeaways from Syngene International Ltd's Q1 FY26…

  • Yatharth Hospital & Trauma Care Services (Q1 FY26)

    International patient business is growing but will remain around 10% of revenue, positively impacting ARPOB without hurting margins. Key concall takeaways from…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Global Health Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Global Health Ltd Q1 FY26 results?

Medanta expects continued strong growth in patient volumes, evidenced by 14% inpatient and 13% outpatient volume growth year-on-year in Q1 FY26. Medanta projects strong growth opportunities driven by expansion and acquisitions aligned with their ecosystem and financial logic (Page 17).

What is Global Health Ltd share price analysis?

Global Health Ltd currently shows a neutral. The stock trades at a P/E of 66.2 with a market cap of ₹37,919 Cr. Investors should review the full earnings analysis for detailed insights.

Is Global Health Ltd planning capital expenditure?

Medanta has a strong cash position with plenty of growth opportunities and ongoing capex commitments, particularly for building out existing hospitals in Delhi, Mumbai, and Guwahati.

Keep Global Health Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.